This is a knockout-validated antibody summary, based on the publications "Distinct roles of programmed death ligand 1 alternative splicing isoforms in colorectal cancer", as cited below [1], and "N6-methyladenosine-modified circIGF2BP3 inhibits CD8+ T-cell responses to facilitate tumor immune evasion by promoting the deubiquitination of PD-L1 in non-small cell lung cancer" for western blot knockout validation (figure s7j) [2]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Figure 1. Immunoblotting for the detection of PD‐L1 expression in RKO cells with the PD‐L1 gene knockout using CRISPR‐Cas9 technology. From [1].

Rabbit monoclonal IgG

Company: Abcam

Antibody: PD-L1

Catalog number: ab205921

Summary: Rabbit monoclonal antibody against recombinant full length protein corresponding to human PD-L1 (extracellular). The immunogen contains the specific extracellular domain of huPD-L1 (Phe19-Thr239). Reacts with human. Suitable for western blot, immunocytochemistry, immunohistochemistry (paraffin) and flow cytometry.

Western blot

Controla and PD‐L1-/- RKO cells.

5% low‐fat milk at room temperature for 1 hour.

Overnight at 4°C.

Secondary antibodies (Odyssey, Li‐COR, Bioscience) for 1 hour at room temperature.

Odyssey system.